Your browser doesn't support javascript.
Reinfection With SARS-CoV-2: Implications for Vaccines.
Cohen, Jeffrey I; Burbelo, Peter D.
  • Cohen JI; Laboratory of Infectious Diseases, National Institutes of Health, Bethesda, Maryland, USA.
  • Burbelo PD; National Institute of Dental and Craniofacial Research, National Institutes of Health, Bethesda, Maryland,USA.
Clin Infect Dis ; 73(11): e4223-e4228, 2021 12 06.
Article in English | MEDLINE | ID: covidwho-1387794
ABSTRACT
Infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has become pandemic and the duration of protective immunity to the virus is unknown. Cases of persons reinfected with the virus are being reported with increasing frequency. At present it is unclear how common reinfection with SARS-CoV-2 is and how long serum antibodies and virus-specific T cells persist after infection. For many other respiratory virus infections, including influenza and the seasonal coronaviruses that cause colds, serum antibodies persist for only months to a few years and reinfections are very common. Here we review what is known about the duration of immunity and reinfection with coronaviruses, including SARS-CoV-2, as well as the duration of immunity to other viruses and virus vaccines. These findings have implications for the need of continued protective measures and for vaccines for persons previously infected with SARS-CoV-2.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Influenza Vaccines / COVID-19 Topics: Vaccines Limits: Humans Language: English Journal: Clin Infect Dis Journal subject: Communicable Diseases Year: 2021 Document Type: Article Affiliation country: CID

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Influenza Vaccines / COVID-19 Topics: Vaccines Limits: Humans Language: English Journal: Clin Infect Dis Journal subject: Communicable Diseases Year: 2021 Document Type: Article Affiliation country: CID